<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Vagus nerve stimulation therapy for the treatment of epilepsy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Vagus nerve stimulation therapy for the treatment of epilepsy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Vagus nerve stimulation therapy for the treatment of epilepsy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven C Schachter, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joseph I Sirven, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Garcia, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 30, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antiseizure medications are the most often used treatment for patients with epilepsy. However, in approximately one-third of people with epilepsy, medications do not completely control seizures [
         <a href="#rid1">
          1
         </a>
         ]. The seizures that occur in these patients are referred to as refractory or drug-resistant.
        </p>
        <p>
         In patients with refractory epilepsy, various combinations of antiseizure medications may be tried. Although combination therapy may help to reduce the total number of seizures, polypharmacy often leads to an increased number of side effects. Nonpharmacologic options are therefore an important component of the overall therapeutic approach to refractory epilepsy. One such option is vagus nerve stimulation (VNS) therapy; others include epilepsy surgery, ketogenic diet, and responsive neurostimulation. Among these, epilepsy surgery is the only potentially curative option. Neuromodulatory options, including VNS, are appropriate to consider in patients who are not candidates for resective epilepsy surgery.
        </p>
        <p>
         This topic reviews the relevant anatomy, possible mechanisms of action, and clinical results of VNS in patients with epilepsy. Other aspects of epilepsy treatment in both children and adults are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2220.html" rel="external">
          "Overview of the management of epilepsy in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2214.html" rel="external">
          "Evaluation and management of drug-resistant epilepsy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">
          "Surgical treatment of epilepsy in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6203.html" rel="external">
          "Seizures and epilepsy in children: Initial treatment and monitoring"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/101361.html" rel="external">
          "Seizures and epilepsy in children: Refractory seizures"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14438.html" rel="external">
          "Ketogenic dietary therapies for the treatment of epilepsy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MECHANISM OF EFFECT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The precise mechanisms by which vagus nerve stimulation (VNS) therapy achieves seizure reduction are not well established. A variety of nonexclusive mechanisms have been proposed and are partially supported by animal and human studies, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Afferent vagal projections through the pontine parabrachial nucleus and thalamus to seizure generating regions in the basal forebrain and insular cortex [
         <a href="#rid2">
          2,3
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Effects on the locus ceruleus, which receives vagal afferent signals from the nucleus tractus solitarius [
         <a href="#rid4">
          4,5
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Desynchronization of hypersynchronized cortical activity (ie, seizure activity), dependent on stimulus frequency and the strength of the electrical current [
         <a href="#rid6">
          6-8
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cortical inhibition secondary to release of inhibitory neurotransmitters, such as glycine and gamma-aminobutyric acid (GABA) [
         <a href="#rid9">
          9,10
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased blood flow and neural activity in the thalamus, limbic system, and multiple cortical regions [
         <a href="#rid11">
          11-21
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         In animal models, a variety of antiseizure properties of VNS have been demonstrated, including abortion of an ongoing seizure, prophylaxis against acute seizure-inducing insults, reduction in chronic seizure frequency in epilepsy models, and inhibition of epileptogenesis in models of seizure kindling [
         <a href="#rid22">
          22-29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3221464953">
         <span class="h1">
          PATIENT SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, vagus nerve stimulation (VNS) therapy is considered a valid treatment option for children and adults with well-documented medically refractory seizures who are opposed to intracranial surgery, are not candidates, or whose medically refractory seizures were not substantially improved by prior intracranial epilepsy surgery [
         <a href="#rid30">
          30,31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2214.html" rel="external">
          "Evaluation and management of drug-resistant epilepsy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">
          "Surgical treatment of epilepsy in adults"
         </a>
         .)
        </p>
        <p>
         The US Food and Drug Administration (FDA) has approved VNS therapy as adjunctive treatment for patients 4 years of age and older with focal seizures that are refractory to antiseizure medications. The approval was based largely on two pivotal randomized trials in this patient population (see
         <a class="local">
          'Focal epilepsy'
         </a>
         below). In Europe, VNS is approved, unrestricted by age, as adjunctive therapy for patients whose epileptic disorder is dominated by focal seizures (with or without secondary generalization) or generalized seizures that are refractory to antiseizure medications.
        </p>
        <p>
         Although there are limited randomized studies in other age groups and seizure types, observational studies reviewed below suggest that the benefits of VNS may extend to a broad range of seizure types [
         <a href="#rid32">
          32,33
         </a>
         ]. The effectiveness of VNS does not appear to vary significantly based on age, neurologic comorbidity, cause of epilepsy, location of the brain from which seizure arise, or epilepsy syndrome.
        </p>
        <p>
         Identification of factors that accurately predict a clinical response to VNS has been elusive [
         <a href="#rid34">
          34-37
         </a>
         ]. Although VNS is effective for seizures that originate from any lobe of the brain, one study found that seizures arising from the frontal lobes responded better than seizures arising from the temporal region [
         <a href="#rid38">
          38
         </a>
         ]. Other studies have suggested that VNS may be more effective in patients who have had epilepsy for a shorter period of time [
         <a href="#rid39">
          39
         </a>
         ] and in patients with seizures beginning after one year of age [
         <a href="#rid32">
          32,40,41
         </a>
         ]. Earlier age of epilepsy onset is also a predictor of medical intractability [
         <a href="#rid42">
          42
         </a>
         ]. Further studies are needed to identify predictive factors associated with a response to VNS.
        </p>
        <p class="headingAnchor" id="H1114788478">
         <span class="h2">
          Focal epilepsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two multicenter, blinded, randomized trials in patients 12 years of age and older with refractory focal epilepsy (more than six seizures per month) have found that active, high-intensity VNS stimulation improves seizure outcomes compared with low-intensity control stimulation [
         <a href="#rid43">
          43-48
         </a>
         ]. In both trials, patients were treated with a mean of two antiseizure medications at study entry; these were not adjusted during the study period. The primary efficacy measure was the percentage change in seizure frequency during VNS treatment (measured over 12 weeks, two weeks after implantation) compared with a 12-week preimplantation baseline.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the E03 study, 114 patients with predominantly focal seizures were enrolled [
         <a href="#rid46">
          46
         </a>
         ]. The high-stimulation group experienced a greater mean reduction in seizure frequency compared with the low-stimulation group (24.5 versus 6.1 percent). More patients in the high-stimulation group experienced a greater than 50 percent reduction in seizures (31 versus 13 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the E05 study, 199 patients with complex partial or secondarily generalized seizures were enrolled [
         <a href="#rid47">
          47
         </a>
         ]. The mean reduction in seizure frequency was greater in the high-stimulation group (28 versus 15 percent). A greater than 75 percent reduction in seizures was achieved in more patients in the high-stimulation group (11 versus 2 percent).
        </p>
        <p>
        </p>
        <p>
         Patients in both studies, as well as 124 other patients who received VNS on a compassionate-use basis, were followed for an additional 12 months [
         <a href="#rid49">
          49-51
         </a>
         ]. All patients received high-stimulation VNS. Median seizure reductions compared with baseline appeared even greater than in the controlled portion of the studies: 34 percent at three months and 45 percent at 12 months. At 12 months, 20 percent of patients achieved seizure reduction of greater than 75 percent.
        </p>
        <p>
         These and other open-label studies suggest that the efficacy of VNS may improve over time [
         <a href="#rid34">
          34,52-58
         </a>
         ]. However, these results should be interpreted with some caution; there were no control groups in these studies. Further, antiseizure medication adjustments, permitted during some of these observational studies, may have contributed to improved seizure control.
        </p>
        <p>
         A third study, referred to as the PULSE trial, was stopped early due to slow recruitment after 112 out of a planned 362 patients were enrolled [
         <a href="#rid59">
          59
         </a>
         ]. PULSE was an open-label randomized trial comparing VNS plus best medical practice (BMP) with BMP alone in adults with refractory focal seizures. In 96 analyzed patients, there were significant between-group differences in favor of VNS plus BMP on measures of quality of life and seizure frequency. Although a greater number of patients in the VNS plus BMP group reported adverse events (43 versus 21 percent), the adverse effects were mostly transient and related to VNS implantation or stimulation. (See
         <a class="local">
          'Side effects and complications'
         </a>
         below.)
        </p>
        <p>
         In addition to randomized trials [
         <a href="#rid48">
          48
         </a>
         ], multiple large case series have reported responder rates (&gt;50 percent reduction of seizures) of 50 to 64 percent in patients implanted with VNS with a follow up time ranging from one to five years [
         <a href="#rid34">
          34,37,39,60,61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H758561088">
         <span class="h2">
          Generalized epilepsies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Case series suggest that VNS is also effective in generalized epilepsy syndromes [
         <a href="#rid32">
          32,37,41,55,60,62
         </a>
         ]. While some studies have found that symptomatic generalized epilepsy is more responsive to VNS than idiopathic syndromes, others have reported the opposite or found no difference [
         <a href="#rid32">
          32,55,63,64
         </a>
         ]. In one of the early randomized trials of VNS, 24 patients had refractory idiopathic generalized epilepsy, and there was a 46 percent median reduction of seizures in this group after three months of treatment [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         A relatively large accumulation of clinical experience with VNS in patients with Lennox-Gastaut syndrome is due in part to the fact that seizures are often medically intractable, and surgical treatment options are limited [
         <a href="#rid62">
          62-73
         </a>
         ]. VNS appears to be very effective in this patient group, leading to a greater than 50 percent reduction in seizure frequency in approximately two-thirds of patients, shortened seizure duration, and a median reduction of one prescribed antiseizure medication [
         <a href="#rid73">
          73
         </a>
         ]. VNS may be particularly effective at reducing atonic and tonic seizures in these patients. (See
         <a class="medical medical_review" href="/z/d/html/138854.html" rel="external">
          "Lennox-Gastaut syndrome"
         </a>
         .)
        </p>
        <p>
         Other refractory epilepsies with onset in childhood also appear to respond to VNS in uncontrolled case series; these include epileptic encephalopathies (eg, Landau Kleffner syndrome), Dravet syndrome (ie, severe myoclonic epilepsy of infancy), tuberous sclerosis complex, and atypical absence epilepsy [
         <a href="#rid32">
          32,40,55,62-69,74-78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3172512509">
         <span class="h2">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to small studies reviewed above in children with specific epilepsy syndromes such as Lennox-Gastaut syndrome, one randomized study and multiple observational studies have examined the efficacy and tolerability of VNS in children.
        </p>
        <p>
         In the only randomized study to date, 41 children (mean age 11 years, range 3 to 17 years), most with intractable focal epilepsy, were randomized to high-output stimulation versus low-output (control) stimulation and followed for 20 weeks [
         <a href="#rid79">
          79
         </a>
         ]. At the end of the blinded randomized treatment phase, the proportion of patients achieving 50 percent or greater reduction in seizure frequency was similar between groups (16 percent in the high-stimulation group versus 21 percent in the low-stimulation group). After a 19-week unblinded add-on phase during which 34 children all received high-output stimulation, 26 percent of patients achieved a 50 percent or greater reduction in seizure frequency and 94 percent of parents or guardians reported positive qualitative effects of treatment.
        </p>
        <p>
         These results contrast with many prior observational studies that suggested that VNS was similarly effective in children compared with adolescents and adults [
         <a href="#rid37">
          37,40,41,62,80,81
         </a>
         ]. A 2021 systematic review and meta-analysis included 98 observational studies, one randomized controlled trial, and 3474 children with drug-resistant epilepsy who were treated with VNS; at last follow-up (mean 2.5 years), the responder rate (&gt;50 percent seizure reduction) associated with VNS was 56 percent, and the pooled seizure freedom rate was 11 percent [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         There are several possible explanations for the discrepancy between the randomized and observational data in children. Some have suggested that the randomized study was under-powered or too short to see the full impact of VNS, since data in adults suggest that improvement may only be seen after a year or longer of stimulation [
         <a href="#rid83">
          83
         </a>
         ]. Alternatively, differences in electrophysiology and incomplete maturation of the vagus nerve in children compared with adults could impact the effectiveness of stimulation [
         <a href="#rid84">
          84
         </a>
         ]. In other reports, VNS has been used with success in children as young as 11 months.
        </p>
        <p class="headingAnchor" id="H3230020137">
         <span class="h2">
          Older adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         Experience with VNS in older patients with epilepsy is limited. The subset of 45 patients in the EO3 and EO5 trials reviewed above who were 50 years of age or older experienced a benefit similar to the population as a whole [
         <a href="#rid85">
          85
         </a>
         ]. However, only eight of these patients were older than 60 years. (See
         <a class="medical medical_review" href="/z/d/html/2225.html" rel="external">
          "Seizures and epilepsy in older adults: Treatment and prognosis", section on 'Other treatments'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3187078791">
         <span class="h2">
          Previous epilepsy surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         VNS treatment has been reported to be successful in patients with previous epilepsy surgery [
         <a href="#rid34">
          34,40,62,63,86,87
         </a>
         ]. In a VNS registry study, the response was favorable but somewhat less so in the 591 surgical patients compared with the 2382 nonsurgical patients; median reduction in seizure frequencies at 3 and 12 months were 43 versus 47 percent and 46 versus 60 percent [
         <a href="#rid88">
          88
         </a>
         ]. While some case series have suggested that the outcomes with VNS may be more favorable in the post-callosotomy group, the VNS registry data suggest that at 12 months, response rates are similar in these two groups.
        </p>
        <p class="headingAnchor" id="H2389442225">
         <span class="h1">
          CONTRAINDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Baseline cardiac conduction disorders are generally considered a contraindication to vagus nerve stimulation (VNS) therapy, given the potential for efferent conduction through the vagus nerve, particularly on the right, to worsen cardiac conduction abnormalities. (See
         <a class="local">
          'Bradycardia'
         </a>
         below.)
        </p>
        <p>
         Sleep apnea is a relative contraindication for VNS (see
         <a class="local">
          'Sleep apnea'
         </a>
         below). Prior to VNS implantation, possible sleep apnea-related symptoms and physical signs should be sought on history and physical examination, and if found, should be pursued by testing to determine whether the patient does have clinically significant sleep apnea. (See
         <a class="medical medical_review" href="/z/d/html/7706.html" rel="external">
          "Clinical presentation and diagnosis of obstructive sleep apnea in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6363.html" rel="external">
          "Evaluation of suspected obstructive sleep apnea in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7701.html" rel="external">
          "Central sleep apnea: Risk factors, clinical presentation, and diagnosis"
         </a>
         .)
        </p>
        <p>
         There are reports that programmable shunt valves can be affected by use of the VNS magnet [
         <a href="#rid89">
          89
         </a>
         ]. VNS stimulation using the magnet should probably be avoided in individuals with programmable shunts.
        </p>
        <p class="headingAnchor" id="H2347896855">
         <span class="h1">
          DEVICE SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vagus nerve stimulation (VNS) is a battery-powered device similar to a cardiac pacemaker. In most models, stimulating leads are surgically placed around the left vagus nerve in the carotid sheath and are connected to an infraclavicular subcutaneous programmable pacemaker  (
         <a class="graphic graphic_figure graphicRef69707" href="/z/d/graphic/69707.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         Because the right vagus nerve provides more innervation to the cardiac atria than the left vagus nerve, electrical stimulation of the left vagus nerve is generally used in clinical practice to avoid adverse cardiac effects [
         <a href="#rid90">
          90
         </a>
         ]. However, right-sided VNS has been reported safe in at least one case series, and in animal studies it appears equally effective against seizures as left-sided stimulation [
         <a href="#rid91">
          91,92
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2254773391">
         <span class="h2">
          Responsive devices
         </span>
         <span class="headingEndMark">
          —
         </span>
         A VNS model that provides responsive stimulation to increases in heart rate that are often associated with seizures was approved by the US Food and Drug Administration (FDA) in 2015 [
         <a href="#rid93">
          93
         </a>
         ]. The responsive stimulation occurs in addition to the automatic intermittent stimulation and in addition to the on-demand stimulation when the patient uses the magnet. It is not yet known whether responsive models are more effective than non-responsive models, and the design of the trials that have been performed does not allow for direct comparison.
        </p>
        <p>
         The rationale for the model is the observation that up to 80 percent of patients experience an acceleration of heart rate when a seizure occurs [
         <a href="#rid94">
          94
         </a>
         ]. The automated stimulation function of this VNS model detects these heart rate changes and automatically responds by sending a programmed stimulation to the vagus nerve. Both seizure-related and non-seizure related increases in heart rate may trigger stimulation.
        </p>
        <p>
         In a multicenter unblinded trial of 20 patients with refractory focal epilepsy who underwent placement of heart-rate responsive VNS, a total of 89 seizures occurred while patients were continuously monitored over three to five days in an epilepsy monitoring unit [
         <a href="#rid95">
          95
         </a>
         ]. Overall, 43 percent of seizures were associated with ≥20 percent rise in heart rate, 35 percent of seizures received automated stimulation, and 21 percent of seizures stopped during automated stimulation (median duration from stimulation to seizure end, 35 seconds). Responder rates (≥50 percent reduction in seizures per month compared with baseline) at 3, 6, and 12 months were 20, 35, and 50 percent, respectively. The mean duty cycle increased from 11 to 16 percent at six months, which represents approximately five additional stimulations per hour compared with standard, non-responsive settings.
        </p>
        <p>
         The device is relatively new, and selection criteria and predictors of benefit have not been established. Pending further data and clinical experience, a heart rate-responsive VNS model may be considered in patients who have documented tachycardia at the onset of seizures and who are not expected to be able to apply on-demand stimulation with the magnet.
        </p>
        <p class="headingAnchor" id="H2205978958">
         <span class="h2">
          Noninvasive systems
         </span>
         <span class="headingEndMark">
          —
         </span>
         An entirely noninvasive, transcutaneous vagal nerve stimulator has been in use in Europe. The device stimulates the auricular branch of the vagus nerve via a small earphone-like stimulator. Although no randomized studies have been done in patients with epilepsy, it appears promising in one pilot study [
         <a href="#rid96">
          96
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1207449727">
         <span class="h2">
          Other emerging technologies
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of additional technologies related to VNS are under development. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A system that combines stimulation and recording of the vagus nerve
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A stimulator that provides unidirectional (ie, afferent-only) stimulation
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1470940135">
         <span class="h1">
          STIMULATION PARAMETERS
         </span>
        </p>
        <p class="headingAnchor" id="H4134500924">
         <span class="h2">
          Initial settings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Typical initiation stimulation parameters are outlined in the table  (
         <a class="graphic graphic_table graphicRef59936" href="/z/d/graphic/59936.html" rel="external">
          table 1
         </a>
         ). Baseline active stimulation consists of a 30 Hz stimulus delivered for 30 seconds every five minutes.
        </p>
        <p>
         More research is needed to determine whether any initiation stimulation settings provide more benefit than standard initial settings [
         <a href="#rid97">
          97,98
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1288080067">
         <span class="h2">
          Adjustments over time
         </span>
         <span class="headingEndMark">
          —
         </span>
         Baseline VNS settings can be adjusted over time at outpatient follow up visits to maximize efficacy and minimize side effects  (
         <a class="graphic graphic_table graphicRef59936" href="/z/d/graphic/59936.html" rel="external">
          table 1
         </a>
         ). Adjustments that may improve efficacy include decreasing off time and increasing the output current. In a retrospective study of 50 children with drug-resistant epilepsy treated with VNS, switching to a rapid duty cycle (off time ≤1.1 minute, keeping the duty cycle less than 50 percent) was associated with an increased response to VNS and was well tolerated [
         <a href="#rid99">
          99
         </a>
         ]. The significance of this finding is uncertain given that prospective studies have shown that efficacy from VNS can increase over time independent of parameter changes.
        </p>
        <p>
         Adjustments that may improve tolerability include decreasing the frequency of the stimulus and decreasing the pulse width.
        </p>
        <p class="headingAnchor" id="H22603033">
         <span class="h2">
          On-demand stimulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For some patients who experience auras, on-demand stimulation with the supplied magnet can be an effective adjunct to chronic stimulation for attenuating or interrupting seizures [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         In one of the initial randomized trials (E03), patients receiving high-stimulation (active) treatment also received an active magnet, while patients in the control group received an inactive magnet [
         <a href="#rid100">
          100
         </a>
         ]. Use of the active magnet terminated more seizures than the inactive magnet (21 versus 12 percent). Similar efficacy was seen in patients with generalized epilepsy. One case series in children reported that 19 of the 27 patients were able to abort or attenuate at least some of their seizures [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2293089360">
         <span class="h1">
          SIDE EFFECTS AND COMPLICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2076237156">
         <span class="h2">
          Voice alteration and other common side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the EO3 study, the most commonly reported side effects of high-stimulation vagus nerve stimulation (VNS) were [
         <a href="#rid46">
          46
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hoarseness (37 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Throat pain (11 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Coughing (7 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shortness of breath (6 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tingling (6 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Muscle pain (6 percent)
        </p>
        <p>
        </p>
        <p>
         Among these, hoarseness was the only side effect that occurred significantly more often with high stimulation than with low stimulation. In the E05 study, shortness of breath and pharyngitis, as well as voice alteration, occurred significantly more often in the high-stimulation group than in the low-stimulation group [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Lowering the pulse width of stimulation can alleviate symptoms and allow for higher stimulation intensities [
         <a href="#rid101">
          101
         </a>
         ]. Lowering the frequency can also attenuate side effects related to VNS stimulation  (
         <a class="graphic graphic_table graphicRef59936" href="/z/d/graphic/59936.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Adjustments over time'
         </a>
         above.)
        </p>
        <p>
         Long-term studies of VNS generally show improved tolerability over time [
         <a href="#rid56">
          56
         </a>
         ]. Among 444 patients who continued VNS after participating in a clinical study, the most commonly reported side effects at the end of the first year post-implantation were voice alteration (29 percent), tingling (12 percent), dyspnea (8 percent), and cough (8 percent); at the end of two years, the prevalence of these complaints was 19, 4, 3, and 6 percent, and at three years, each of these was present in less than 3 percent. High retention rates (&gt;70 percent) may be an indicator of how well VNS is tolerated.
        </p>
        <p class="headingAnchor" id="H3357830397">
         <span class="h2">
          Implantation site infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection of the subcutaneous pocket that holds the VNS generator, usually with Staphylococcus aureus, complicates surgery in 2 to 7 percent of cases [
         <a href="#rid37">
          37,102-105
         </a>
         ]. The risk of infection may be higher in children compared with adults [
         <a href="#rid30">
          30
         </a>
         ]. Systemic antibiotics along with explantation of the device and/or open wound debridement is usually required. (See
         <a class="medical medical_review" href="/z/d/html/2146.html" rel="external">
          "Infections involving cardiac implantable electronic devices: Epidemiology, microbiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Other surgical complications associated with VNS are infrequent. Early reports of electrode failure and lead fracture appear to be largely resolved with improvements in the device and enhancements in surgical techniques and postoperative care [
         <a href="#rid106">
          106-109
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3108838697">
         <span class="h2">
          Bradycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Physiologic studies have generally found no clinically relevant effects of chronic VNS on cardiorespiratory function [
         <a href="#rid110">
          110-112
         </a>
         ]. However, bradycardia followed by transient asystole lasting up to 45 seconds has been reported in association with the lead test conducted during VNS implantation (the initial lead test, which is performed in the operating room when the VNS is being implanted for the first time) in approximately 0.1 percent of cases [
         <a href="#rid113">
          113-115
         </a>
         ]. These cases occurred with the earliest VNS devices when a 1.0 milliamps test stimulus was given. Changes in the programming now allow for testing at 0.25 milliamps; there have been no reported cases of asystole in the operating room in association with contemporary testing parameters.
        </p>
        <p>
         Complete heart block due to atrioventricular nodal block has been documented in three patients with no reported adverse effects [
         <a href="#rid116">
          116
         </a>
         ]. In some cases, a rechallenge stimulus is uneventful, and the VNS has been implanted successfully without adverse consequences. In general, baseline cardiac conduction disorders are considered a contraindication to VNS.
        </p>
        <p>
         Two case reports describe VNS-induced episodes of bradycardia and asystole occurring two and nine years after device implantation [
         <a href="#rid117">
          117,118
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H544875407">
         <span class="h2">
          Vocal cord paralysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unilateral vocal cord paralysis occurs in approximately 1 percent of cases, and is attributed to intraoperative manipulation of the recurrent laryngeal nerve [
         <a href="#rid37">
          37,46,60
         </a>
         ]. Most of these recover. Two cases of delayed permanent vocal cord paralysis occurring several weeks after implantation appeared to be self-inflicted by patients who manipulated the device externally, presumably placing traction on the recurrent laryngeal nerve [
         <a href="#rid119">
          119
         </a>
         ]. This phenomenon appears analogous to the "twiddler's syndrome" described in individuals with cardiac pacemakers. (See
         <a class="medical medical_review" href="/z/d/html/989.html" rel="external">
          "Cardiac implantable electronic devices: Long-term complications", section on 'Twiddler's syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3390443075">
         <span class="h2">
          Aspiration
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are some reports that children with severe developmental delay on assisted feeding may aspirate. This seems to occur if the child is fed during the time that the VNS is delivering its programmed stimulation [
         <a href="#rid62">
          62,108,120,121
         </a>
         ]. However, the association between aspiration and VNS has been disputed [
         <a href="#rid120">
          120
         </a>
         ]. Nonetheless, there are reports that using the magnet to inactivate the VNS during mealtime controls this problem.
        </p>
        <p class="headingAnchor" id="H3089946674">
         <span class="h2">
          Sleep apnea
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sleep apnea is a relative contraindication for VNS (see
         <a class="local">
          'Contraindications'
         </a>
         above) based on observations that VNS can induce or aggravate a sleep apnea syndrome [
         <a href="#rid122">
          122-125
         </a>
         ]. VNS is associated with more frequent apnea and hypopnea episodes in sleep, but this appears clinically relevant mainly in those with preexisting sleep apnea.
        </p>
        <p>
         Lowering stimulus frequency can ameliorate VNS-related apnea and hypopnea [
         <a href="#rid123">
          123
         </a>
         ]. Continuous positive airway pressure (CPAP) may be required for some cases [
         <a href="#rid124">
          124
         </a>
         ]. Botulinum toxin was reported to be helpful in one case of VNS-induced laryngospasm [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2598440141">
         <span class="h2">
          Other rare side effects
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aside from recurrent laryngeal nerve palsy, other cranial nerve palsies that can complicate VNS implant include Horner syndrome and facial paralysis [
         <a href="#rid127">
          127
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pneumothorax has been described in at least one patient [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some patients experience uncomfortable spasms of the left chest wall, which has been demonstrated to be due to collateral spread of stimulation to phrenic nerve, causing contraction of the left hemidiaphragm [
         <a href="#rid128">
          128
         </a>
         ]. Contraction of the left anterior sternocleidomastoid muscle may also occur as a result of current stimulating adjacent structures [
         <a href="#rid129">
          129
         </a>
         ]. These symptoms are often precipitated by assumption of certain postures or movement and are relieved by changing position.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         While gastrointestinal side effects might be expected with VNS, reports of this are infrequent. One patient experienced chronic diarrhea after VNS implant, but this is exceptional [
         <a href="#rid130">
          130
         </a>
         ]. One case series documented clinically significant weight loss in 17 of 27 patients who had received VNS [
         <a href="#rid131">
          131
         </a>
         ]. This observation requires further confirmation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Forced normalization refers to a phenomenon of psychiatric disturbances that emerge in some patients with long-standing, high-frequency seizures when their seizures are dramatically reduced. This has been described with VNS, usually with reduction in seizure frequency of greater than 75 percent [
         <a href="#rid132">
          132,133
         </a>
         ]. Some, but not all, of these patients exhibited psychiatric symptoms, including psychosis prior to VNS implantation. Psychosis in these cases usually responds to psychotropic medication; in some cases, lowering the potency of antiseizure treatment is required.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients are cautioned by the manufacturer not to undergo short-wave, microwave, or therapeutic ultrasound diathermy, which in theory could cause the VNS generator or lead to heat up and cause thermal tissue damage. There are no documented cases of this complication in VNS-treated patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3960744816">
         <span class="h1">
          OTHER PRACTICAL ISSUES
         </span>
        </p>
        <p class="headingAnchor" id="H4100573637">
         <span class="h2">
          MRI compatibility
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of any implanted pacemaker is widely regarded as a contraindication to magnetic resonance imaging (MRI). Potential problems include considerable heating at the lead tip, which has been documented in animal experiments, and programming changes of pacing parameters [
         <a href="#rid134">
          134
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/113084.html" rel="external">
          "Patient evaluation for metallic or electrical implants, devices, or foreign bodies before magnetic resonance imaging", section on 'Assessing implants, devices, or foreign bodies for MRI'
         </a>
         .)
        </p>
        <p>
         However, MRI is safe using 1.5 Tesla (T) or 3 T scanners for patients with an implanted VNS if performed according to guidelines from the VNS manufacturer. Clinicians should refer to online
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.livanova.com%2Fepilepsy-vnstherapy%2Fen-us%2Fhcp%2Fmri-safety&amp;token=cL6ll9A%2FVcH9e6bZvOobeN01BCcZ4E8mnRFwqrCdYR4bPTbsb5odvuhMwoZgpiK6ok4t0h8%2FUXVccyi1zel4XoRnlAWR9xdgTUCBR5%2Bb6dI%3D&amp;TOPIC_ID=2229" target="_blank">
          MRI safety guidelines
         </a>
         and downloadable
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdynamic.cyberonics.com%2Fmanuals%2Femanual_download.asp%3Flang%3DEnglish-US%26docid%3D%7B039BFFD9-74A7-46BB-96A6-367EE5BB3E89%7D&amp;token=XJd5zjCoqL%2FKYEqvYZ72AB9puM2GuBotgVazJuQnVQ6BTlNS2T18RtjH1JBRBWy7%2BUrkPCSFh4dG6eylzn407dVp1jYXA2PlZ1Gc%2B2%2FHUVIOcyZ4ab8lD4oc1hLYQShmly2xYOWHXdc4YFV5HqkLaLpaM8Pd7aPOZ5IMTR3J4jY%3D&amp;TOPIC_ID=2229" target="_blank">
          MRI Physician’s Manual
         </a>
         from the manufacturer to determine specific MRI scan conditions for patients with an implanted VNS (or incompletely explanted VNS, as many patients cannot have complete removal of the leads).
        </p>
        <p>
         Use of MRI outside the limits outlined by the manufacturer cannot be considered safe and is not recommended. VNS remains contraindicated in 7 T MRI environments.
        </p>
        <p>
         A 2021 systematic review, with a total of 216 patients, found that cranial MRI of patients with an implanted VNS system can be completed and is tolerable and safe using 1.5 T or 3 T MRI when performed in adherence to guidelines from the VNS manufacturer [
         <a href="#rid135">
          135
         </a>
         ]. An earlier ex vivo study of temperature changes associated with different MRI conditions found no clinically significant temperature changes under the guidelines outlined by the manufacturer [
         <a href="#rid136">
          136
         </a>
         ]. Excessive heating was observed with the use of body coil during imaging of the neck and shoulder but not of the lumbar spine; however, the number of experiments in the latter case was limited. VNS device function was not affected by the MRI procedure.
        </p>
        <p>
         Of note, hospitals and imaging centers may have their own safety committees that may at times be more conservative than manufacturer recommendations. For this reason, it is often wise to obtain a 3 T brain MRI prior to the insertion of VNS in patients who have not previously had high-resolution brain imaging, so that surgical resective options may be revisited if appropriate after VNS.
        </p>
        <p class="headingAnchor" id="H518579769">
         <span class="h2">
          Battery life
         </span>
         <span class="headingEndMark">
          —
         </span>
         As the VNS generator battery is expended, seizure frequency may increase in some patients [
         <a href="#rid137">
          137,138
         </a>
         ]. Others may note decreased or irregular perception of stimulation [
         <a href="#rid138">
          138
         </a>
         ]. Fortunately, the end of battery service can be predicted with the current VNS model, allowing for elective generator replacement before the battery is fully depleted.
        </p>
        <p>
         A reason for re-implanting a new battery before the old one is depleted is that a small number of patients who initially responded to VNS reportedly did not regain seizure control with VNS reimplant after a period of seizure-worsening associated with an expended battery [
         <a href="#rid137">
          137
         </a>
         ]. As a result of these cases, it is generally agreed that patients who experience efficacy with VNS should have the generator battery replaced before it is expended.
        </p>
        <p class="headingAnchor" id="H341287865">
         <span class="h2">
          Cost
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is an initial cost to implanting a VNS (estimated USD $15,000 to $25,000). Due to concerns about medical costs, there have been several studies which have tried to assess the economic impact of adding VNS to the patient’s existing therapy. In these studies, economic analyses suggest that VNS reduces doctor visits, hospitalizations, and other epilepsy-related direct medical care costs when these are averaged over the lifespan of the generator [
         <a href="#rid139">
          139-142
         </a>
         ].
        </p>
        <p>
         In one study that included over 1600 epilepsy patients enrolled in Medicaid (mean age 29 years), VNS was associated with decreased resource utilization and epilepsy-related clinical events that resulted in a net cost savings by 1.5 years post-implantation [
         <a href="#rid143">
          143
         </a>
         ]. Similar cost savings have been found in children [
         <a href="#rid144">
          144
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          NONSEIZURE OUTCOMES
         </span>
        </p>
        <p class="headingAnchor" id="H2358387404">
         <span class="h2">
          Quality of life
         </span>
         <span class="headingEndMark">
          —
         </span>
         Quality of life measures improve in most studies of vagus nerve stimulation (VNS) in both children and adults [
         <a href="#rid40">
          40,41,62,72,145-149
         </a>
         ]. While this effect is greatest in those who achieve the highest reduction in seizures, there appears to be an effect that is independent of reduction in seizure frequency, and may relate to independent effects of VNS on mood, alertness, and other factors. As with seizure reduction, improvement in quality of life measures also appear to increase over time.
        </p>
        <p class="headingAnchor" id="H3643368197">
         <span class="h2">
          Mood symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence indicating that VNS may improve mood and other depressive symptoms in patients with epilepsy is inconclusive [
         <a href="#rid150">
          150-152
         </a>
         ]. In some but not all studies, a positive effect of VNS on mood appeared to correlate with reduction in seizures. VNS is under investigation as a treatment for major depression in nonepileptic patients. Although open-label studies suggest that the intervention may have some efficacy, a randomized trial found no benefit compared with sham stimulation over a 10-week treatment phase [
         <a href="#rid153">
          153
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16518.html" rel="external">
          "Unipolar depression in adults: Treatment with surgical approaches", section on 'Vagus nerve stimulation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2140303765">
         <span class="h2">
          Daytime sleepiness
         </span>
         <span class="headingEndMark">
          —
         </span>
         VNS may improve daytime alertness and vigilance and reduce daytime sleepiness despite its potential to exacerbate sleep apnea (see
         <a class="local">
          'Sleep apnea'
         </a>
         above) [
         <a href="#rid68">
          68,146,154,155
         </a>
         ]. In one series, this was documented by longer mean sleep latency times and improved scores on a daytime sleepiness scale. Improved alertness occurred even in patients without significant reduction in seizure frequency [
         <a href="#rid155">
          155
         </a>
         ]. Vagal stimulation of brainstem centers known to promote alertness (eg, parabrachial nucleus, locus ceruleus) may mediate this effect.
        </p>
        <p>
         There appears to be a differential effect of high- versus low-intensity stimulus on sleep and alertness. Low-intensity stimulation (&lt;1.5 mA) more consistently improves daytime alertness than higher intensity stimulation [
         <a href="#rid146">
          146,155
         </a>
         ]. In one study, higher intensity stimulation was associated with reduced rapid eye movement (REM) sleep [
         <a href="#rid154">
          154
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2625338768">
         <span class="h2">
          Behavior
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with autism and intellectual disability have demonstrated improved behavioral outcomes with VNS treatment of their epilepsy. Benefits include improved alertness, mental age, and performance on functional measures and some cognitive tests, as well as reduced autistic behaviors [
         <a href="#rid40">
          40,64,70,74,76,145,156
         </a>
         ]. In some cases, these improvements appear to be independent of seizure control. In adult patients, cognition does not appear to be positively or negatively affected by VNS treatment [
         <a href="#rid157">
          157,158
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1228421003">
         <span class="h2">
          Reduction in antiseizure medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reduction of antiseizure medications can be of primary benefit to patients and may also affect the quality of life outcomes discussed above. In most cases, patients with VNS continue to require medical treatment [
         <a href="#rid159">
          159
         </a>
         ]. However, some patients are able to reduce one or more drugs and/or doses, and a few patients are seizure free with VNS and no antiseizure medication treatment [
         <a href="#rid32">
          32,160
         </a>
         ].
        </p>
        <p>
         There is limited information regarding the frequency of this outcome. Larger series indicate that most patients remain on the same number of antiseizure medications after VNS, without specifically discussing dose alterations [
         <a href="#rid40">
          40,56,159
         </a>
         ]. Smaller case series report higher percentages of antiseizure medication dose or medication reductions, perhaps reflecting a more aggressive effort of the clinicians involved in achieving this goal [
         <a href="#rid160">
          160
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1080259107">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neither sudden death nor overall mortality rates appear to be increased in patients receiving VNS compared with expected rates in the refractory epilepsy population.
        </p>
        <p>
         In fact, there is evidence that VNS may reduce the rates of sudden unexplained death in epilepsy (SUDEP): in a cohort of 1819 individuals with VNS followed for &gt;3000 person-years from VNS implantation, the SUDEP rate was 5.5 per 1000 over the first two years, but only 1.7 per 1000 thereafter [
         <a href="#rid161">
          161
         </a>
         ]. By contrast, a smaller retrospective study with longer median follow up observed a trend towards decreased overall mortality rates in the years following VNS implantation, but no change in the SUDEP rate over time [
         <a href="#rid162">
          162
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2215.html" rel="external">
          "Sudden unexpected death in epilepsy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H258648272">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113971.html" rel="external">
          "Society guideline links: Seizures and epilepsy in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/113981.html" rel="external">
          "Society guideline links: Seizures and epilepsy in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2852974673">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surgical evaluation is recommended for patients with refractory focal seizures (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). Eligible patients with medically refractory epilepsy are more likely to achieve seizure remission with epilepsy surgery than with other treatment modalities. (See
         <a class="medical medical_review" href="/z/d/html/91820.html" rel="external">
          "Surgical treatment of epilepsy in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vagus nerve stimulation (VNS) is a battery-powered device similar to a cardiac pacemaker. Stimulating leads are surgically placed around the left vagus nerve in the carotid sheath  (
         <a class="graphic graphic_figure graphicRef69707" href="/z/d/graphic/69707.html" rel="external">
          figure 1
         </a>
         ). VNS has multiple antiseizure properties, but the exact mechanisms of effect remain unclear. (See
         <a class="local">
          'Mechanism of effect'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         VNS is a valid treatment option for patients with medically refractory epilepsy. This includes patients who are not candidates for resective surgery, those who opt not to undergo brain surgery, and those whose seizures persist after resective epilepsy surgery. (See
         <a class="local">
          'Patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Controlled trials in individuals greater than 12 years of age with focal epilepsy indicate that 30 to 40 percent achieve a greater than 50 percent reduction in seizure frequency. Open-label studies suggest that these benefits may increase over time and adjustment of parameter settings. (See
         <a class="local">
          'Focal epilepsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are conflicting data on the efficacy of VNS in younger children. Most open-label studies suggest that younger children and individuals with other seizure types and epilepsy syndromes (eg, Lennox-Gastaut syndrome) can benefit from VNS. However, a single, small, randomized study found no benefit of VNS compared with low-stimulation control in patients 3 to 17 years in age. (See
         <a class="local">
          'Generalized epilepsies'
         </a>
         above and
         <a class="local">
          'Children'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Side effects that occur during stimulation in a minority of patients are usually mild to moderate in severity and diminish with time or reduction in stimulation intensity. These include voice alteration and tingling. (See
         <a class="local">
          'Voice alteration and other common side effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serious adverse events are rare and include infections, cardiac arrhythmias, and aspiration. Infections may be more common in children than adults. (See
         <a class="local">
          'Side effects and complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Magnetic resonance imaging (MRI) in patients with VNS is limited to brain MRI under specific conditions outlined by the manufacturer. (See
         <a class="local">
          'MRI compatibility'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H587205730">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Steven Karceski, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314.
          </a>
         </li>
         <li class="breakAll">
          Saper CB. The central autonomic system. In: The Rat Nervous System, 2nd ed, Paxinos G (Ed), Academic Press, San Diego 1995. p.107.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cechetto DF, Saper CB. Evidence for a viscerotopic sensory representation in the cortex and thalamus in the rat. J Comp Neurol 1987; 262:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naritoku DK, Terry WJ, Helfert RH. Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve. Epilepsy Res 1995; 22:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krahl SE, Clark KB, Smith DC, Browning RA. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation. Epilepsia 1998; 39:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chase MH, Sterman MB, Clemente CD. Cortical and subcortical patterns of response to afferent vagal stimulation. Exp Neurol 1966; 16:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chase MH, Nakamura Y, Clemente CD, Sterman MB. Afferent vagal stimulation: neurographic correlates of induced EEG synchronization and desynchronization. Brain Res 1967; 5:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chase MH, Nakamura Y, Clemente CD, Sterman MB. Cortical and subcortical EEG patterns of response to afferent abdominal vagal stimulation: neurographic correlates. Physiol Behav 1968; 3:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Lazzaro V, Oliviero A, Pilato F, et al. Effects of vagus nerve stimulation on cortical excitability in epileptic patients. Neurology 2004; 62:2310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrosu F, Serra A, Maleci A, et al. Correlation between GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy. Epilepsy Res 2003; 55:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garnett ES, Nahmias C, Scheffel A, et al. Regional cerebral blood flow in man manipulated by direct vagal stimulation. Pacing Clin Electrophysiol 1992; 15:1579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ko D, Heck C, Grafton S, et al. Vagus nerve stimulation activates central nervous system structures in epileptic patients during PET H2(15)O blood flow imaging. Neurosurgery 1996; 39:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henry TR, Votaw JR, Pennell PB, et al. Acute blood flow changes and efficacy of vagus nerve stimulation in partial epilepsy. Neurology 1999; 52:1166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ring HA, White S, Costa DC, et al. A SPECT study of the effect of vagal nerve stimulation on thalamic activity in patients with epilepsy. Seizure 2000; 9:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Laere K, Vonck K, Boon P, et al. Perfusion SPECT changes after acute and chronic vagus nerve stimulation in relation to prestimulus condition and long-term clinical efficacy. J Nucl Med 2002; 43:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vonck K, Boon P, Van Laere K, et al. Acute single photon emission computed tomographic study of vagus nerve stimulation in refractory epilepsy. Epilepsia 2000; 41:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohning DE, Lomarev MP, Denslow S, et al. Feasibility of vagus nerve stimulation-synchronized blood oxygenation level-dependent functional MRI. Invest Radiol 2001; 36:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mu Q, Bohning DE, Nahas Z, et al. Acute vagus nerve stimulation using different pulse widths produces varying brain effects. Biol Psychiatry 2004; 55:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sucholeiki R, Alsaadi TM, Morris GL 3rd, et al. fMRI in patients implanted with a vagal nerve stimulator. Seizure 2002; 11:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narayanan JT, Watts R, Haddad N, et al. Cerebral activation during vagus nerve stimulation: a functional MR study. Epilepsia 2002; 43:1509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu WC, Mosier K, Kalnin AJ, Marks D. BOLD fMRI activation induced by vagus nerve stimulation in seizure patients. J Neurol Neurosurg Psychiatry 2003; 74:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLachlan RS. Suppression of interictal spikes and seizures by stimulation of the vagus nerve. Epilepsia 1993; 34:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodbury DM, Woodbury JW. Effects of vagal stimulation on experimentally induced seizures in rats. Epilepsia 1990; 31 Suppl 2:S7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodbury JW, Woodbury DM. Vagal stimulation reduces the severity of maximal electroshock seizures in intact rats: use of a cuff electrode for stimulating and recording. Pacing Clin Electrophysiol 1991; 14:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zabara J. Inhibition of experimental seizures in canines by repetitive vagal stimulation. Epilepsia 1992; 33:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockard JS, Congdon WC, DuCharme LL. Feasibility and safety of vagal stimulation in monkey model. Epilepsia 1990; 31 Suppl 2:S20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takaya M, Terry WJ, Naritoku DK. Vagus nerve stimulation induces a sustained anticonvulsant effect. Epilepsia 1996; 37:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Guardiola A, Martínez A, Valdés-Cruz A, et al. Vagus nerve prolonged stimulation in cats: effects on epileptogenesis (amygdala electrical kindling): behavioral and electrographic changes. Epilepsia 1999; 40:822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magdaleno-Madrigal VM, Valdés-Cruz A, Martínez-Vargas D, et al. Effect of electrical stimulation of the nucleus of the solitary tract on the development of electrical amygdaloid kindling in the cat. Epilepsia 2002; 43:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris GL 3rd, Gloss D, Buchhalter J, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013; 81:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher RS, Handforth A. Reassessment: vagus nerve stimulation for epilepsy: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1999; 53:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labar D, Murphy J, Tecoma E. Vagus nerve stimulation for medication-resistant generalized epilepsy. E04 VNS Study Group. Neurology 1999; 52:1510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Touma L, Dansereau B, Chan AY, et al. Neurostimulation in people with drug-resistant epilepsy: Systematic review and meta-analysis from the ILAE Surgical Therapies Commission. Epilepsia 2022; 63:1314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labar D. Vagus nerve stimulation for 1 year in 269 patients on unchanged antiepileptic drugs. Seizure 2004; 13:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tecoma ES, Iragui VJ. Vagus nerve stimulation use and effect in epilepsy: what have we learned? Epilepsy Behav 2006; 8:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Janszky J, Hoppe M, Behne F, et al. Vagus nerve stimulation: predictors of seizure freedom. J Neurol Neurosurg Psychiatry 2005; 76:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott RE, Morsi A, Kalhorn SP, et al. Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: long-term outcomes and predictors of response. Epilepsy Behav 2011; 20:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burakgazi AZ, Burakgazi-Dalkilic E, Caputy AJ, Potolicchio SJ. The correlation between vagus nerve stimulation efficacy and partial onset epilepsies. J Clin Neurophysiol 2011; 28:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renfroe JB, Wheless JW. Earlier use of adjunctive vagus nerve stimulation therapy for refractory epilepsy. Neurology 2002; 59:S26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy JV, Torkelson R, Dowler I, et al. Vagal nerve stimulation in refractory epilepsy: the first 100 patients receiving vagal nerve stimulation at a pediatric epilepsy center. Arch Pediatr Adolesc Med 2003; 157:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patwardhan RV, Stong B, Bebin EM, et al. Efficacy of vagal nerve stimulation in children with medically refractory epilepsy. Neurosurgery 2000; 47:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berg AT, Levy SR, Novotny EJ, Shinnar S. Predictors of intractable epilepsy in childhood: a case-control study. Epilepsia 1996; 37:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Menachem E, Mañon-Espaillat R, Ristanovic R, et al. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group. Epilepsia 1994; 35:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsay RE, Uthman BM, Augustinsson LE, et al. Vagus nerve stimulation for treatment of partial seizures: 2. Safety, side effects, and tolerability. First International Vagus Nerve Stimulation Study Group. Epilepsia 1994; 35:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George R, Salinsky M, Kuzniecky R, et al. Vagus nerve stimulation for treatment of partial seizures: 3. Long-term follow-up on first 67 patients exiting a controlled study. First International Vagus Nerve Stimulation Study Group. Epilepsia 1994; 35:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group. Neurology 1995; 45:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 1998; 51:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panebianco M, Rigby A, Weston J, Marson AG. Vagus nerve stimulation for partial seizures. Cochrane Database Syst Rev 2015; :CD002896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michael JE, Wegener K, Barnes DW. Vagus nerve stimulation for intractable seizures: one year follow-up. J Neurosci Nurs 1993; 25:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salinsky MC, Uthman BM, Ristanovic RK, et al. Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial. Vagus Nerve Stimulation Study Group. Arch Neurol 1996; 53:1176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeGiorgio CM, Schachter SC, Handforth A, et al. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia 2000; 41:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuba R, Brázdil M, Novák Z, et al. Effect of vagal nerve stimulation on patients with bitemporal epilepsy. Eur J Neurol 2003; 10:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uthman BM, Reichl AM, Dean JC, et al. Effectiveness of vagus nerve stimulation in epilepsy patients: a 12-year observation. Neurology 2004; 63:1124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spanaki MV, Allen LS, Mueller WM, Morris GL 3rd. Vagus nerve stimulation therapy: 5-year or greater outcome at a university-based epilepsy center. Seizure 2004; 13:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy JV. Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group. J Pediatr 1999; 134:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris GL 3rd, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 1999; 53:1731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siddiqui F, Herial NA, Ali II. Cumulative effect of vagus nerve stimulators on intractable seizures observed over a period of 3years. Epilepsy Behav 2010; 18:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orosz I, McCormick D, Zamponi N, et al. Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children. Epilepsia 2014; 55:1576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryvlin P, Gilliam FG, Nguyen DK, et al. The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial. Epilepsia 2014; 55:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vonck K, Thadani V, Gilbert K, et al. Vagus nerve stimulation for refractory epilepsy: a transatlantic experience. J Clin Neurophysiol 2004; 21:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Herdt V, Boon P, Ceulemans B, et al. Vagus nerve stimulation for refractory epilepsy: a Belgian multicenter study. Eur J Paediatr Neurol 2007; 11:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundgren J, Amark P, Blennow G, et al. Vagus nerve stimulation in 16 children with refractory epilepsy. Epilepsia 1998; 39:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Menachem E, Hellström K, Waldton C, Augustinsson LE. Evaluation of refractory epilepsy treated with vagus nerve stimulation for up to 5 years. Neurology 1999; 52:1265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker AP, Polkey CE, Binnie CD, et al. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics 1999; 103:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buoni S, Zannolli R, Macucci F, et al. Delayed response of seizures with vagus nerve stimulation in Lennox-Gastaut syndrome. Neurology 2004; 63:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helmers SL, Al-Jayyousi M, Madsen J. Adjunctive treatment in Lennox-Gastaut syndrome using vagal nerve stimulation. Epilepsia 1998; 39 (Suppl 6):169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy JV, Hornig G. Chronic intermittent stimulation of the left vagal nerve in nine children with Lennox-Gastaut syndrome. Epilepsia 1998; 39 (Suppl 6):169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frost M, Gates J, Helmers SL, et al. Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome. Epilepsia 2001; 42:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosain S, Nikalov B, Harden C, et al. Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. J Child Neurol 2000; 15:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aldenkamp AP, Van de Veerdonk SH, Majoie HJ, et al. Effects of 6 months of treatment with vagus nerve stimulation on behavior in children with lennox-gastaut syndrome in an open clinical and nonrandomized study. Epilepsy Behav 2001; 2:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parain D, Penniello MJ, Berquen P, et al. Vagal nerve stimulation in tuberous sclerosis complex patients. Pediatr Neurol 2001; 25:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahwan A, Bailey C, Maxiner W, Harvey AS. Vagus nerve stimulation for refractory epilepsy in children: More to VNS than seizure frequency reduction. Epilepsia 2009; 50:1220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kostov K, Kostov H, Taubøll E. Long-term vagus nerve stimulation in the treatment of Lennox-Gastaut syndrome. Epilepsy Behav 2009; 16:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Majoie HJ, Berfelo MW, Aldenkamp AP, et al. Vagus nerve stimulation in patients with catastrophic childhood epilepsy, a 2-year follow-up study. Seizure 2005; 14:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andriola MR, Vitale SA. Vagus Nerve Stimulation in the Developmentally Disabled. Epilepsy Behav 2001; 2:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy JV, Wheless JW, Schmoll CM. Left vagal nerve stimulation in six patients with hypothalamic hamartomas. Pediatr Neurol 2000; 23:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Major P, Thiele EA. Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex. Epilepsy Behav 2008; 13:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott RE, Carlson C, Kalhorn SP, et al. Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery. Epilepsy Behav 2009; 16:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klinkenberg S, Aalbers MW, Vles JS, et al. Vagus nerve stimulation in children with intractable epilepsy: a randomized controlled trial. Dev Med Child Neurol 2012; 54:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boon P, Vonck K, Van Walleghem P, et al. Programmed and magnet-induced vagus nerve stimulation for refractory epilepsy. J Clin Neurophysiol 2001; 18:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coykendall DS, Gauderer MW, Blouin RR, Morales A. Vagus nerve stimulation for the management of seizures in children: an 8-year experience. J Pediatr Surg 2010; 45:1479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain P, Arya R. Vagus Nerve Stimulation and Seizure Outcomes in Pediatric Refractory Epilepsy: Systematic Review and Meta-analysis. Neurology 2021; 96:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pressler RM. Vagus nerve stimulation in children with intractable epilepsy. Dev Med Child Neurol 2012; 54:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koo B. EEG changes with vagus nerve stimulation. J Clin Neurophysiol 2001; 18:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sirven JI, Sperling M, Naritoku D, et al. Vagus nerve stimulation therapy for epilepsy in older adults. Neurology 2000; 54:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hornig GW, Murphy JV, Schallert G, Tilton C. Left vagus nerve stimulation in children with refractory epilepsy: an update. South Med J 1997; 90:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koutroumanidis M, Binnie CD, Hennessy MJ, et al. VNS in patients with previous unsuccessful resective epilepsy surgery: antiepileptic and psychotropic effects. Acta Neurol Scand 2003; 107:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amar AP, Apuzzo ML, Liu CY. Vagus nerve stimulation therapy after failed cranial surgery for intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry. Neurosurgery 2004; 55:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tatum WO 4th, Helmers SL. Vagus nerve stimulation and magnet use: optimizing benefits. Epilepsy Behav 2009; 15:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saper CB, Kibbe MR, Hurley KM, et al. Brain natriuretic peptide-like immunoreactive innervation of the cardiovascular and cerebrovascular systems in the rat. Circ Res 1990; 67:1345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGregor A, Wheless J, Baumgartner J, Bettis D. Right-sided vagus nerve stimulation as a treatment for refractory epilepsy in humans. Epilepsia 2005; 46:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krahl SE, Senanayake SS, Handforth A. Right-sided vagus nerve stimulation reduces generalized seizure severity in rats as effectively as left-sided. Epilepsy Res 2003; 56:1.
          </a>
         </li>
         <li class="breakAll">
          http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P970003S202 (Accessed on September 08, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggleston KS, Olin BD, Fisher RS. Ictal tachycardia: the head-heart connection. Seizure 2014; 23:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher RS, Afra P, Macken M, et al. Automatic Vagus Nerve Stimulation Triggered by Ictal Tachycardia: Clinical Outcomes and Device Performance--The U.S. E-37 Trial. Neuromodulation 2016; 19:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stefan H, Kreiselmeyer G, Kerling F, et al. Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: a proof of concept trial. Epilepsia 2012; 53:e115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuba R, Guzaninová M, Brázdil M, et al. Effect of vagal nerve stimulation on interictal epileptiform discharges: a scalp EEG study. Epilepsia 2002; 43:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeGiorgio C, Heck C, Bunch S, et al. Vagus nerve stimulation for epilepsy: randomized comparison of three stimulation paradigms. Neurology 2005; 65:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kayyali H, Abdelmoity S, Bansal L, et al. The Efficacy and Safety of Rapid Cycling Vagus Nerve Stimulation in Children With Intractable Epilepsy. Pediatr Neurol 2020; 109:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris GL 3rd. A retrospective analysis of the effects of magnet-activated stimulation in conjunction with vagus nerve stimulation therapy. Epilepsy Behav 2003; 4:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liporace J, Hucko D, Morrow R, et al. Vagal nerve stimulation: adjustments to reduce painful side effects. Neurology 2001; 57:885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Révész D, Rydenhag B, Ben-Menachem E. Complications and safety of vagus nerve stimulation: 25 years of experience at a single center. J Neurosurg Pediatr 2016; 18:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smyth MD, Tubbs RS, Bebin EM, et al. Complications of chronic vagus nerve stimulation for epilepsy in children. J Neurosurg 2003; 99:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel NC, Edwards MS. Vagal nerve stimulator pocket infections. Pediatr Infect Dis J 2004; 23:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortler M, Luef G, Kofler A, et al. Deep wound infection after vagus nerve stimulator implantation: treatment without removal of the device. Epilepsia 2001; 42:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patil A, Chand A, Andrews R. Single incision for implanting a vagal nerve stimulator system (VNSS): technical note. Surg Neurol 2001; 55:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaughn BV, Bernard E, Lannon S, et al. Intraoperative methods for confirmation of correct placement of the vagus nerve stimulator. Epileptic Disord 2001; 3:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy JV, Hornig GW, Schallert GS, Tilton CL. Adverse events in children receiving intermittent left vagal nerve stimulation. Pediatr Neurol 1998; 19:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schachter SC. Vagus nerve stimulation therapy summary: five years after FDA approval. Neurology 2002; 59:S15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frei MG, Osorio I. Left vagus nerve stimulation with the neurocybernetic prosthesis has complex effects on heart rate and on its variability in humans. Epilepsia 2001; 42:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Binks AP, Paydarfar D, Schachter SC, et al. High strength stimulation of the vagus nerve in awake humans: a lack of cardiorespiratory effects. Respir Physiol 2001; 127:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galli R, Limbruno U, Pizzanelli C, et al. Analysis of RR variability in drug-resistant epilepsy patients chronically treated with vagus nerve stimulation. Auton Neurosci 2003; 107:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asconapé JJ, Moore DD, Zipes DP, et al. Bradycardia and asystole with the use of vagus nerve stimulation for the treatment of epilepsy: a rare complication of intraoperative device testing. Epilepsia 1999; 40:1452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tatum WO 4th, Moore DB, Stecker MM, et al. Ventricular asystole during vagus nerve stimulation for epilepsy in humans. Neurology 1999; 52:1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andriola MR, Rosenzweig T, Vlay S. Vagus nerve stimulator (VNS): induction of asystole during implantation with subsequent successful stimulation. Epilepsia 2000; 41 (Suppl 7):223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ali II, Pirzada NA, Kanjwal Y, et al. Complete heart block with ventricular asystole during left vagus nerve stimulation for epilepsy. Epilepsy Behav 2004; 5:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amark P, Stödberg T, Wallstedt L. Late onset bradyarrhythmia during vagus nerve stimulation. Epilepsia 2007; 48:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iriarte J, Urrestarazu E, Alegre M, et al. Late-onset periodic asystolia during vagus nerve stimulation. Epilepsia 2009; 50:928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalkanis JG, Krishna P, Espinosa JA, Naritoku DK. Self-inflicted vocal cord paralysis in patients with vagus nerve stimulators. Report of two cases. J Neurosurg 2002; 96:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schallert G, Foster J, Lindquist N, Murphy JV. Chronic stimulation of the left vagal nerve in children: effect on swallowing. Epilepsia 1998; 39:1113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundgren J, Ekberg O, Olsson R. Aspiration: a potential complication to vagus nerve stimulation. Epilepsia 1998; 39:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes MD, Chang M, Kapur V. Sleep apnea and excessive daytime somnolence induced by vagal nerve stimulation. Neurology 2003; 61:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malow BA, Edwards J, Marzec M, et al. Effects of vagus nerve stimulation on respiration during sleep: a pilot study. Neurology 2000; 55:1450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marzec M, Edwards J, Sagher O, et al. Effects of vagus nerve stimulation on sleep-related breathing in epilepsy patients. Epilepsia 2003; 44:930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvadé A, Ryvlin P, Rossetti AO. Impact of vagus nerve stimulation on sleep-related breathing disorders in adults with epilepsy. Epilepsy Behav 2018; 79:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar S, Sharafkhaneh A, Edmonds J, et al. Treatment of vns-induced laryngospasm with botulinum toxin. Neurology 2009; 73:1808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim W, Clancy RR, Liu GT. Horner syndrome associated with implantation of a vagus nerve stimulator. Am J Ophthalmol 2001; 131:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leijten FS, Van Rijen PC. Stimulation of the phrenic nerve as a complication of vagus nerve pacing in a patient with epilepsy. Neurology 1998; 51:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iriarte J, Artieda J, Alegre M, et al. Spasm of the sternocleidomastoid muscle induced by vagal nerve stimulation. Neurology 2001; 57:2319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanossian N, Haut S. Chronic diarrhea associated with vagal nerve stimulation. Neurology 2002; 58:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burneo JG, Faught E, Knowlton R, et al. Weight loss associated with vagus nerve stimulation. Neurology 2002; 59:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumer D, Davies K, Alexander A, Morgan S. Major Psychiatric Disorders Subsequent to Treating Epilepsy by Vagus Nerve Stimulation. Epilepsy Behav 2001; 2:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prater JF. Recurrent depression with vagus nerve stimulation. Am J Psychiatry 2001; 158:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luechinger R, Zeijlemaker VA, Pedersen EM, et al. In vivo heating of pacemaker leads during magnetic resonance imaging. Eur Heart J 2005; 26:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fetzer S, Dibué M, Nagel AM, Trollmann R. A systematic review of magnetic resonance imaging in patients with an implanted vagus nerve stimulation system. Neuroradiology 2021; 63:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shellock FG, Begnaud J, Inman DM. Vagus nerve stimulation therapy system: in vitro evaluation of magnetic resonance imaging-related heating and function at 1.5 and 3 tesla. Neuromodulation 2006; 9:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tatum WO 4th, Ferreira JA, Benbadis SR, et al. Vagus nerve stimulation for pharmacoresistant epilepsy: clinical symptoms with end of service. Epilepsy Behav 2004; 5:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vonck K, Dedeurwaerdere S, De Groote L, et al. Generator replacement in epilepsy patients treated with vagus nerve stimulation. Seizure 2005; 14:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boon P, Vonck K, D'Have M, et al. Cost-benefit of vagus nerve stimulation for refractory epilepsy. Acta Neurol Belg 1999; 99:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boon P, D'Havé M, Van Walleghem P, et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia 2002; 43:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forbes RB, Macdonald S, Eljamel S, Roberts RC. Cost-utility analysis of vagus nerve stimulators for adults with medically refractory epilepsy. Seizure 2003; 12:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Menachem E, Hellström K, Verstappen D. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology 2002; 59:S44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helmers SL, Duh MS, Guérin A, et al. Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav 2011; 22:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helmers SL, Duh MS, Guérin A, et al. Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. Eur J Paediatr Neurol 2012; 16:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gates J, Huf R, Frost M. Vagus Nerve Stimulation for Patients in Residential Treatment Facilities. Epilepsy Behav 2001; 2:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galli R, Bonanni E, Pizzanelli C, et al. Daytime vigilance and quality of life in epileptic patients treated with vagus nerve stimulation. Epilepsy Behav 2003; 4:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cramer JA. Exploration of Changes in Health-Related Quality of Life after 3 Months of Vagus Nerve Stimulation. Epilepsy Behav 2001; 2:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrow JI, Bingham E, Craig JJ, Gray WJ. Vagal nerve stimulation in patients with refractory epilepsy. Effect on seizure frequency, severity and quality of life. Seizure 2000; 9:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helmers SL, Wheless JW, Frost M, et al. Vagus nerve stimulation therapy in pediatric patients with refractory epilepsy: retrospective study. J Child Neurol 2001; 16:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elger G, Hoppe C, Falkai P, et al. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res 2000; 42:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harden CL, Pulver MC, Ravdin LD, et al. A Pilot Study of Mood in Epilepsy Patients Treated with Vagus Nerve Stimulation. Epilepsy Behav 2000; 1:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoppe C, Helmstaedter C, Scherrmann J, Elger CE. Self-Reported Mood Changes following 6 Months of Vagus Nerve Stimulation in Epilepsy Patients. Epilepsy Behav 2001; 2:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzo P, Beelke M, De Carli F, et al. Chronic vagus nerve stimulation improves alertness and reduces rapid eye movement sleep in patients affected by refractory epilepsy. Sleep 2003; 26:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malow BA, Edwards J, Marzec M, et al. Vagus nerve stimulation reduces daytime sleepiness in epilepsy patients. Neurology 2001; 57:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huf RL, Mamelak A, Kneedy-Cayem K. Vagus nerve stimulation therapy: 2-year prospective open-label study of 40 subjects with refractory epilepsy and low IQ who are living in long-term care facilities. Epilepsy Behav 2005; 6:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dodrill CB, Morris GL. Effects of Vagal Nerve Stimulation on Cognition and Quality of Life in Epilepsy. Epilepsy Behav 2001; 2:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schachter SC. Vagus nerve stimulation: mood and cognitive effects. Epilepsy Behav 2004; 5 Suppl 1:S56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labar DR. Antiepileptic drug use during the first 12 months of vagus nerve stimulation therapy: a registry study. Neurology 2002; 59:S38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tatum WO, Johnson KD, Goff S, et al. Vagus nerve stimulation and drug reduction. Neurology 2001; 56:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Annegers JF, Coan SP, Hauser WA, Leestma J. Epilepsy, vagal nerve stimulation by the NCP system, all-cause mortality, and sudden, unexpected, unexplained death. Epilepsia 2000; 41:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Granbichler CA, Nashef L, Selway R, Polkey CE. Mortality and SUDEP in epilepsy patients treated with vagus nerve stimulation. Epilepsia 2015; 56:291.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2229 Version 41.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10660394" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Early identification of refractory epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10660394" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Early identification of refractory epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2442207" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Evidence for a viscerotopic sensory representation in the cortex and thalamus in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8565967" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Regional induction of fos immunoreactivity in the brain by anticonvulsant stimulation of the vagus nerve.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9670898" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5923482" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cortical and subcortical patterns of response to afferent vagal stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6033149" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Afferent vagal stimulation: neurographic correlates of induced EEG synchronization and desynchronization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Cortical and subcortical EEG patterns of response to afferent abdominal vagal stimulation: neurographic correlates
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15210904" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Effects of vagus nerve stimulation on cortical excitability in epileptic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12948617" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Correlation between GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1383972" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Regional cerebral blood flow in man manipulated by direct vagal stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8832691" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Vagus nerve stimulation activates central nervous system structures in epileptic patients during PET H2(15)O blood flow imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10214738" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Acute blood flow changes and efficacy of vagus nerve stimulation in partial epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10985992" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A SPECT study of the effect of vagal nerve stimulation on thalamic activity in patients with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12050316" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Perfusion SPECT changes after acute and chronic vagus nerve stimulation in relation to prestimulus condition and long-term clinical efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10802767" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Acute single photon emission computed tomographic study of vagus nerve stimulation in refractory epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11500598" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Feasibility of vagus nerve stimulation-synchronized blood oxygenation level-dependent functional MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15050863" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Acute vagus nerve stimulation using different pulse widths produces varying brain effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12018958" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : fMRI in patients implanted with a vagal nerve stimulator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12460253" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Cerebral activation during vagus nerve stimulation: a functional MR study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12754361" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : BOLD fMRI activation induced by vagus nerve stimulation in seizure patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8404747" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Suppression of interictal spikes and seizures by stimulation of the vagus nerve.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2226368" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effects of vagal stimulation on experimentally induced seizures in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1705342" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Vagal stimulation reduces the severity of maximal electroshock seizures in intact rats: use of a cuff electrode for stimulating and recording.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1464256" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Inhibition of experimental seizures in canines by repetitive vagal stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2226362" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Feasibility and safety of vagal stimulation in monkey model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8917063" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Vagus nerve stimulation induces a sustained anticonvulsant effect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10403204" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Vagus nerve prolonged stimulation in cats: effects on epileptogenesis (amygdala electrical kindling): behavioral and electrographic changes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12199721" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Effect of electrical stimulation of the nucleus of the solitary tract on the development of electrical amygdaloid kindling in the cat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23986299" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10489023" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Reassessment: vagus nerve stimulation for epilepsy: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10227649" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Vagus nerve stimulation for medication-resistant generalized epilepsy. E04 VNS Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35352349" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Neurostimulation in people with drug-resistant epilepsy: Systematic review and meta-analysis from the ILAE Surgical Therapies Commission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15276142" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Vagus nerve stimulation for 1 year in 269 patients on unchanged antiepileptic drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16376157" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Vagus nerve stimulation use and effect in epilepsy: what have we learned?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15716532" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Vagus nerve stimulation: predictors of seizure freedom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21144802" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: long-term outcomes and predictors of response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21811127" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The correlation between vagus nerve stimulation efficacy and partial onset epilepsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12270965" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Earlier use of adjunctive vagus nerve stimulation therapy for refractory epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12796236" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Vagal nerve stimulation in refractory epilepsy: the first 100 patients receiving vagal nerve stimulation at a pediatric epilepsy center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11126906" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Efficacy of vagal nerve stimulation in children with medically refractory epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8603620" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Predictors of intractable epilepsy in childhood: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8026408" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8026409" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Vagus nerve stimulation for treatment of partial seizures: 2. Safety, side effects, and tolerability. First International Vagus Nerve Stimulation Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8026410" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Vagus nerve stimulation for treatment of partial seizures: 3. Long-term follow-up on first 67 patients exiting a controlled study. First International Vagus Nerve Stimulation Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7854516" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. The Vagus Nerve Stimulation Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9674777" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25835947" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Vagus nerve stimulation for partial seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8106830" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Vagus nerve stimulation for intractable seizures: one year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8912492" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial. Vagus Nerve Stimulation Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10999559" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12535002" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Effect of vagal nerve stimulation on patients with bitemporal epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15452317" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Effectiveness of vagus nerve stimulation in epilepsy patients: a 12-year observation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15519919" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Vagus nerve stimulation therapy: 5-year or greater outcome at a university-based epilepsy center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10228290" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10563620" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20580901" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Cumulative effect of vagus nerve stimulators on intractable seizures observed over a period of 3years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25231724" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24754318" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15509917" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Vagus nerve stimulation for refractory epilepsy: a transatlantic experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17395507" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Vagus nerve stimulation for refractory epilepsy: a Belgian multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9701369" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Vagus nerve stimulation in 16 children with refractory epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10214754" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Evaluation of refractory epilepsy treated with vagus nerve stimulation for up to 5 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10103302" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Vagal nerve stimulation in epileptic encephalopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15505192" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Delayed response of seizures with vagus nerve stimulation in Lennox-Gastaut syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Adjunctive treatment in Lennox-Gastaut syndrome using vagal nerve stimulation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Chronic intermittent stimulation of the left vagal nerve in nine children with Lennox-Gastaut syndrome
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11580762" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Vagus nerve stimulation in children with refractory seizures associated with Lennox-Gastaut syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10961788" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Vagus nerve stimulation treatment for Lennox-Gastaut syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12609211" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Effects of 6 months of treatment with vagus nerve stimulation on behavior in children with lennox-gastaut syndrome in an open clinical and nonrandomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11587875" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Vagal nerve stimulation in tuberous sclerosis complex patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19170732" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Vagus nerve stimulation for refractory epilepsy in children: More to VNS than seizure frequency reduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19699154" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Long-term vagus nerve stimulation in the treatment of Lennox-Gastaut syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15642494" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Vagus nerve stimulation in patients with catastrophic childhood epilepsy, a 2-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12609196" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Vagus Nerve Stimulation in the Developmentally Disabled.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11020644" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Left vagal nerve stimulation in six patients with hypothalamic hamartomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18468492" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19767244" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22540141" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Vagus nerve stimulation in children with intractable epilepsy: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11709644" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Programmed and magnet-induced vagus nerve stimulation for refractory epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20638528" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Vagus nerve stimulation for the management of seizures in children: an 8-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33849993" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Vagus Nerve Stimulation and Seizure Outcomes in Pediatric Refractory Epilepsy: Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22803764" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Vagus nerve stimulation in children with intractable epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11709649" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : EEG changes with vagus nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10720294" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Vagus nerve stimulation therapy for epilepsy in older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9160063" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Left vagus nerve stimulation in children with refractory epilepsy: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12580861" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : VNS in patients with previous unsuccessful resective epilepsy surgery: antiepileptic and psychotropic effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15509315" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Vagus nerve stimulation therapy after failed cranial surgery for intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19361573" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Vagus nerve stimulation and magnet use: optimizing benefits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1978807" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Brain natriuretic peptide-like immunoreactive innervation of the cardiovascular and cerebrovascular systems in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15660773" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Right-sided vagus nerve stimulation as a treatment for refractory epilepsy in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14529948" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Right-sided vagus nerve stimulation reduces generalized seizure severity in rats as effectively as left-sided.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14529948" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Right-sided vagus nerve stimulation reduces generalized seizure severity in rats as effectively as left-sided.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24698385" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Ictal tachycardia: the head-heart connection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26663671" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Automatic Vagus Nerve Stimulation Triggered by Ictal Tachycardia: Clinical Outcomes and Device Performance--The U.S. E-37 Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22554199" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: a proof of concept trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12366734" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Effect of vagal nerve stimulation on interictal epileptiform discharges: a scalp EEG study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16043810" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Vagus nerve stimulation for epilepsy: randomized comparison of three stimulation paradigms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32461031" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : The Efficacy and Safety of Rapid Cycling Vagus Nerve Stimulation in Children With Intractable Epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14698710" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : A retrospective analysis of the effects of magnet-activated stimulation in conjunction with vagus nerve stimulation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11552021" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Vagal nerve stimulation: adjustments to reduce painful side effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27015521" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Complications and safety of vagus nerve stimulation: 25 years of experience at a single center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12959437" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Complications of chronic vagus nerve stimulation for epilepsy in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15247613" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Vagal nerve stimulator pocket infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11207797" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Deep wound infection after vagus nerve stimulator implantation: treatment without removal of the device.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11301092" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Single incision for implanting a vagal nerve stimulator system (VNSS): technical note.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11431169" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Intraoperative methods for confirmation of correct placement of the vagus nerve stimulator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9682884" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Adverse events in children receiving intermittent left vagal nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12270963" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Vagus nerve stimulation therapy summary: five years after FDA approval.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11554886" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Left vagus nerve stimulation with the neurocybernetic prosthesis has complex effects on heart rate and on its variability in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11504585" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : High strength stimulation of the vagus nerve in awake humans: a lack of cardiorespiratory effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12927227" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Analysis of RR variability in drug-resistant epilepsy patients chronically treated with vagus nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10528943" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Bradycardia and asystole with the use of vagus nerve stimulation for the treatment of epilepsy: a rare complication of intraoperative device testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10214755" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Ventricular asystole during vagus nerve stimulation for epilepsy in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Vagus nerve stimulator (VNS): induction of asystole during implantation with subsequent successful stimulation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15380133" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Complete heart block with ventricular asystole during left vagus nerve stimulation for epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17381444" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Late onset bradyarrhythmia during vagus nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19055490" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Late-onset periodic asystolia during vagus nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12005405" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Self-inflicted vocal cord paralysis in patients with vagus nerve stimulators. Report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9776333" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Chronic stimulation of the left vagal nerve in children: effect on swallowing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738680" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Aspiration: a potential complication to vagus nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14581678" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Sleep apnea and excessive daytime somnolence induced by vagal nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11094096" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Effects of vagus nerve stimulation on respiration during sleep: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12823576" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Effects of vagus nerve stimulation on sleep-related breathing in epilepsy patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29287215" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Impact of vagus nerve stimulation on sleep-related breathing disorders in adults with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19933985" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Treatment of vns-induced laryngospasm with botulinum toxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11239877" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Horner syndrome associated with implantation of a vagus nerve stimulator.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9781571" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Stimulation of the phrenic nerve as a complication of vagus nerve pacing in a patient with epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11756622" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Spasm of the sternocleidomastoid muscle induced by vagal nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11805274" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Chronic diarrhea associated with vagal nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12177391" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Weight loss associated with vagus nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12609285" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Major Psychiatric Disorders Subsequent to Treating Epilepsy by Vagus Nerve Stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11329411" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Recurrent depression with vagus nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15618060" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : In vivo heating of pacemaker leads during magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33846830" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : A systematic review of magnetic resonance imaging in patients with an implanted vagus nerve stimulation system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22151708" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Vagus nerve stimulation therapy system: in vitro evaluation of magnetic resonance imaging-related heating and function at 1.5 and 3 tesla.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14751218" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Vagus nerve stimulation for pharmacoresistant epilepsy: clinical symptoms with end of service.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15694561" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Generator replacement in epilepsy patients treated with vagus nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10674145" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Cost-benefit of vagus nerve stimulation for refractory epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11879393" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12810336" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Cost-utility analysis of vagus nerve stimulators for adults with medically refractory epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12270968" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21872534" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22261080" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12609390" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Vagus Nerve Stimulation for Patients in Residential Treatment Facilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12697145" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Daytime vigilance and quality of life in epileptic patients treated with vagus nerve stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12609284" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Exploration of Changes in Health-Related Quality of Life after 3 Months of Vagus Nerve Stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10986004" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Vagal nerve stimulation in patients with refractory epilepsy. Effect on seizure frequency, severity and quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11732771" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Vagus nerve stimulation therapy in pediatric patients with refractory epilepsy: retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11074193" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Vagus nerve stimulation is associated with mood improvements in epilepsy patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12609137" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : A Pilot Study of Mood in Epilepsy Patients Treated with Vagus Nerve Stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12609210" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Self-Reported Mood Changes following 6 Months of Vagus Nerve Stimulation in Epilepsy Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16139580" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12938816" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Chronic vagus nerve stimulation improves alertness and reduces rapid eye movement sleep in patients affected by refractory epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11552020" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Vagus nerve stimulation reduces daytime sleepiness in epilepsy patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15820352" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Vagus nerve stimulation therapy: 2-year prospective open-label study of 40 subjects with refractory epilepsy and low IQ who are living in long-term care facilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12609181" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Effects of Vagal Nerve Stimulation on Cognition and Quality of Life in Epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14725847" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Vagus nerve stimulation: mood and cognitive effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12270967" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Antiepileptic drug use during the first 12 months of vagus nerve stimulation therapy: a registry study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11261422" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Vagus nerve stimulation and drug reduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10802760" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Epilepsy, vagal nerve stimulation by the NCP system, all-cause mortality, and sudden, unexpected, unexplained death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25580645" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Mortality and SUDEP in epilepsy patients treated with vagus nerve stimulation.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
